Augmenting antidepressants with deep transcranial magnetic stimulation (DTMS) in treatment-resistant major depression
This open label study examines the clinical value of Brainsway Deep TMS (Transcranial Magnetic Stimulation) as an augmenting tool for treatment-resistant depression (TRD; n=17). In this study, 4 weeks of daily deep TMS sessions led to high levels of response and remission rates, significant alleviation of symptoms, and improved quality of life. The study shows that Deep Transcranial Magnetic Stimulation is effective, safe and relatively well tolerated as an augmenting tool for antidepressants in severe TRD.
Brainsway's international website includes clinical and regulatory data for indications which were not cleared by the FDA for use in the United States.
This site is not intended for residents of the United States, its territories, and Puerto Rico.
The FDA cleared Brainsway's Deep TMS system for use in the U.S for treatment of depressive episodes in adult patients suffering from Major Depressive Disorder who failed to achieve satisfactory improvement from previous anti-depressant medication treatment in the current episode.
Would you like to proceed to the international website? To proceed click here
or click here to close this window